Skip to main content
Equibles
ACTU logo

ACTU · Actuate Therapeutics, Inc. · Metrics

Track ACTU — free

Use ACTU with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ACTU.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.30 +0.01 (+1.75%) At close · Nov 11
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on the above matters, we have concluded that there is substantial doubt regarding the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$7.26M
Shares
24.01M
Volume · Nov 11 94.93K Avg daily vol (3M) 422.63K

ACTU metrics

63 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.30
Market cap
$7.26M

Price action

23 metrics
Price change (1W)
-18.3%
Price change (30D)
-35.2%
Price change (3M)
-68.8%
Price change (6M)
-89.8%
Price change (YTD)
-95.1%
Price change (1Y)
-95.1%
Trailing year
Price change (5Y)
—
52-week high
$7.63
52-week low
$0.30
Change from 52-week high
-96.0%
Change from 52-week low
+1.8%
Annualized volatility
118.8%
Annualized volatility (3M)
156.4%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.8
RSI (14D)
31.7
Price vs SMA 50
-57.3%
Price vs SMA 200
-84.5%
Avg volume (3M)
422,631
Relative volume
0.2
Average dollar volume
$379,938

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
24.01M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
7.3
reciprocal yield 13.6%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-281.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$20.77M
Net income (TTM)
−$20.45M
Trailing 12 months
Diluted EPS (TTM)
$-0.88
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.90
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.89
Operating cash flow per diluted share (TTM)
$-0.87
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.39
Stock compensation per diluted share (TTM)
$0.26
Book value per share
$0.34

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+21.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-2,067.8%
Return on assets
-393.4%
Debt / equity
—
Current ratio
1.2
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.2
Interest coverage
-1,025.8
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$4.43M
Latest balance sheet
Cash & equivalents
$4.43M
Total assets
$5.20M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$19.84M
Capital expenditures (TTM)
—
R&D (TTM)
$8.94M
SG&A (TTM)
—
Stock compensation (TTM)
$6.04M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
62
13F filer change QoQ
+1
Institutional ownership
56.0%
Conviction holders (share of 13F filers)
1.6%
Crowding (high-turnover and private-fund holders)
44.1%
Private-fund adviser ownership
43.7%
Active holders' share change QoQ
+1.2%
Holder tenure
6.5
Price vs estimated holder cost
-74.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
3.0%

Short interest

3 metrics
Short interest
5.4%
Latest settlement · 2.1 days to cover
Days to cover
2.1d
Short-squeeze score
43 / 100

Insider activity

2 metrics
Net insider buying (90D)
$50,000
Insider-sentiment score
83 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1652935 CUSIP 005083100 13F (30d) 18 filings 18 filers Visit website Investor relations